Skip to main content
Erschienen in: Supportive Care in Cancer 10/2005

01.10.2005 | Original Article

Prevalence of complementary and alternative medicine use in cancer patients during treatment

verfasst von: Jennifer S. Yates, Karen M. Mustian, Gary R. Morrow, Leslie J. Gillies, Devi Padmanaban, James N. Atkins, Brian Issell, Jeffrey J. Kirshner, Lauren K. Colman

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2005

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

To assess complementary and alternative medicine (CAM) therapies being utilized by cancer patients during treatment and communication about CAM usage between the patient and physician.

Patients and methods

Newly diagnosed cancer patients receiving chemotherapy or radiation therapy were recruited to complete a CAM survey within 2 weeks after the termination of treatment. Patients were queried on which CAM modalities they utilized and whether or not they were discussed with either their oncologist or primary care physician.

Main results

Of the patients surveyed, 91% reported using at least one form of CAM. The most widely used forms of CAM were prayer, relaxation and exercise. CAM users tended to be women chemotherapy patients with at least a high school education. Of the patients using CAM, 57% discussed the use of at least one of these therapies with their oncologist or primary care physician. The most frequent CAM modalities discussed with at least one physician were diets, massage, and herbal medicine.

Conclusions

An overwhelming proportion of cancer patients are using CAM, particularly prayer, relaxation, and exercise. However, patients may not discuss the use of CAMs at all or fully with their physician; if they do, it is most likely to be their oncologist, but not about the most frequently used CAMs. Future research needs to assess effective ways for oncologists to gather information about CAM usage by patients during allopathic treatment and discern ways these therapies may enhance or interfere with traditional cancer treatments.
Literatur
1.
Zurück zum Zitat Adler SR, Fosket JR (1999) Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. J Fam Pract 48:453–458PubMed Adler SR, Fosket JR (1999) Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. J Fam Pract 48:453–458PubMed
3.
Zurück zum Zitat Balneaves LG, Kristjanson LJ, Tataryn D (1999) Beyond convention: describing complementary therapy use by women living with breast cancer. Patient Educ Couns 38:143–153 Balneaves LG, Kristjanson LJ, Tataryn D (1999) Beyond convention: describing complementary therapy use by women living with breast cancer. Patient Educ Couns 38:143–153
4.
Zurück zum Zitat Begbie SD, Kerestes ZL, Bell DR (1996) Patterns of alternative medicine use by cancer patients. Med J Aust 165:545–548 Begbie SD, Kerestes ZL, Bell DR (1996) Patterns of alternative medicine use by cancer patients. Med J Aust 165:545–548
5.
Zurück zum Zitat Bernstein BJ, Grasso T (2001) Prevalence of complementary and alternative medicine use in cancer patients. Oncology 15:1267–1272 Bernstein BJ, Grasso T (2001) Prevalence of complementary and alternative medicine use in cancer patients. Oncology 15:1267–1272
6.
Zurück zum Zitat Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D, Haines-Kamka T (2000) Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 18:2515–2521PubMed Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D, Haines-Kamka T (2000) Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 18:2515–2521PubMed
7.
Zurück zum Zitat Canales MK, Geller BM (2003) Surviving breast cancer: the role of complementary therapies. Fam Commun Health 26:11–24 Canales MK, Geller BM (2003) Surviving breast cancer: the role of complementary therapies. Fam Commun Health 26:11–24
8.
Zurück zum Zitat Dooley MJ, Lee DY, Marriott JL (2004) Practitioners’ sources of clinical information on complementary and alternative medicine in oncology. Support Care Cancer 12:114–119 Dooley MJ, Lee DY, Marriott JL (2004) Practitioners’ sources of clinical information on complementary and alternative medicine in oncology. Support Care Cancer 12:114–119
9.
Zurück zum Zitat Downer SM, Cody MM, McCluskey P, Wilson PD, Arnott SJ, Lister TA, Slevin ML (1994) Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 309:86–89PubMed Downer SM, Cody MM, McCluskey P, Wilson PD, Arnott SJ, Lister TA, Slevin ML (1994) Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 309:86–89PubMed
10.
Zurück zum Zitat Ernst E (2000) The role of complementary and alternative medicine in cancer. Lancet Oncol 1:176–180 Ernst E (2000) The role of complementary and alternative medicine in cancer. Lancet Oncol 1:176–180
11.
Zurück zum Zitat Ernst E, Cassileth BR (1998) The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 83:777–782CrossRefPubMed Ernst E, Cassileth BR (1998) The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 83:777–782CrossRefPubMed
12.
Zurück zum Zitat Feather BL, Wainstock JM, Remington A, Ringenberg QS (1988) Postmastectomy educational needs and social support. J Cancer Educ 3:135–144 Feather BL, Wainstock JM, Remington A, Ringenberg QS (1988) Postmastectomy educational needs and social support. J Cancer Educ 3:135–144
13.
Zurück zum Zitat Henderson JW, Donatelle RJ (2004) Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern Ther Health Med 10:52–57 Henderson JW, Donatelle RJ (2004) Complementary and alternative medicine use by women after completion of allopathic treatment for breast cancer. Altern Ther Health Med 10:52–57
14.
Zurück zum Zitat Jordan ML, Delunas LR (2001) Quality of life and patterns of nontraditional therapy use by patients with cancer. Oncol Nurs Forum 28:1107–1113 Jordan ML, Delunas LR (2001) Quality of life and patterns of nontraditional therapy use by patients with cancer. Oncol Nurs Forum 28:1107–1113
15.
Zurück zum Zitat Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg D (2000) Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst 92:42–47CrossRefPubMed Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg D (2000) Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst 92:42–47CrossRefPubMed
16.
Zurück zum Zitat Lengacher CA, Bennett MP, Kip KE, Keller R, LaVance MS, Smith LS, Cox CE (2002) Frequency of use of complementary and alternative medicine in women with breast cancer. Oncol Nurs Forum 29:1445–1452PubMed Lengacher CA, Bennett MP, Kip KE, Keller R, LaVance MS, Smith LS, Cox CE (2002) Frequency of use of complementary and alternative medicine in women with breast cancer. Oncol Nurs Forum 29:1445–1452PubMed
17.
Zurück zum Zitat Morris KT, Johnson N, Homer L, Walts D (2000) A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 179:407–411CrossRefPubMed Morris KT, Johnson N, Homer L, Walts D (2000) A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 179:407–411CrossRefPubMed
18.
Zurück zum Zitat Morrow GR, Hickok JT, Burish TG, Rosenthal SN (1996) Frequency and clinical implications of delayed nausea and delayed emesis. Am J Clin Oncol 19:199–203CrossRefPubMed Morrow GR, Hickok JT, Burish TG, Rosenthal SN (1996) Frequency and clinical implications of delayed nausea and delayed emesis. Am J Clin Oncol 19:199–203CrossRefPubMed
19.
Zurück zum Zitat Munstedt K, Kirsch K, Milch W, Sachsse S, Vahrson H (1996) Unconventional cancer therapy—survey of patients with gynecological malignancy. Arch Gynecol Obstet 258:81–88CrossRefPubMed Munstedt K, Kirsch K, Milch W, Sachsse S, Vahrson H (1996) Unconventional cancer therapy—survey of patients with gynecological malignancy. Arch Gynecol Obstet 258:81–88CrossRefPubMed
20.
Zurück zum Zitat Navo MA, Phan J, Vaughan C, Palmer JL, Michaud L, Jones KL, Bodurka DC, Basen-Engquist K, Hortobagyi GN, Kavanagh JJ, Smith JA (2004) An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 22:671–677 Navo MA, Phan J, Vaughan C, Palmer JL, Michaud L, Jones KL, Bodurka DC, Basen-Engquist K, Hortobagyi GN, Kavanagh JJ, Smith JA (2004) An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. J Clin Oncol 22:671–677
21.
Zurück zum Zitat NCCAM (2002) What is complementary and alternative medicine (CAM)? (publication no. D156). NCCAM, National Institutes of Health, Bethesda, MD NCCAM (2002) What is complementary and alternative medicine (CAM)? (publication no. D156). NCCAM, National Institutes of Health, Bethesda, MD
22.
Zurück zum Zitat Newell S, Sanson-Fisher RW (2000) Australian oncologists’ self-reported knowledge and attitudes about non-traditional therapies used by cancer patients. Med J Aust 172:110–113 Newell S, Sanson-Fisher RW (2000) Australian oncologists’ self-reported knowledge and attitudes about non-traditional therapies used by cancer patients. Med J Aust 172:110–113
23.
Zurück zum Zitat Ott MJ, Lynch M (2002) Integrating complementary and conventional symptom management in a cancer center. Oncol Nurs Forum 29:25–27 Ott MJ, Lynch M (2002) Integrating complementary and conventional symptom management in a cancer center. Oncol Nurs Forum 29:25–27
24.
Zurück zum Zitat Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ, Marshall LM (2002) Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med 8:477–485 Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ, Marshall LM (2002) Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med 8:477–485
25.
Zurück zum Zitat Ponholzer A, Struhal G, Madersbacher S (2003) Frequent use of complementary medicine by prostate cancer patients. Eur Urol 43:604–608 Ponholzer A, Struhal G, Madersbacher S (2003) Frequent use of complementary medicine by prostate cancer patients. Eur Urol 43:604–608
26.
Zurück zum Zitat Redeker NS, Lev EL, Ruggiero J (2000) Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Sch Inq Nurs Pract 14:275–290 Redeker NS, Lev EL, Ruggiero J (2000) Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Sch Inq Nurs Pract 14:275–290
27.
Zurück zum Zitat Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed
28.
Zurück zum Zitat Richardson MA, Straus SE (2002) Complementary and alternative medicine: opportunities and challenges for cancer management and research. Semin Oncol 29:531–545CrossRefPubMed Richardson MA, Straus SE (2002) Complementary and alternative medicine: opportunities and challenges for cancer management and research. Semin Oncol 29:531–545CrossRefPubMed
29.
Zurück zum Zitat Risberg T, Kaasa S, Wist E, Melsom H (1997) Why are cancer patients using non-proven complementary therapies? A cross-sectional multicentre study in Norway. Eur J Cancer 33:575–580CrossRefPubMed Risberg T, Kaasa S, Wist E, Melsom H (1997) Why are cancer patients using non-proven complementary therapies? A cross-sectional multicentre study in Norway. Eur J Cancer 33:575–580CrossRefPubMed
30.
Zurück zum Zitat Savard J, Morin CM (2001) Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 19:895–908 Savard J, Morin CM (2001) Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 19:895–908
31.
Zurück zum Zitat Sparber A, Bauer L, Curt G, Eisenberg D, Levin T, Parks S, Steinberg SM, Wootton J (2000) Use of complementary medicine by adult patients participating in cancer control trials. Oncol Nurs Forum 27:623–630 Sparber A, Bauer L, Curt G, Eisenberg D, Levin T, Parks S, Steinberg SM, Wootton J (2000) Use of complementary medicine by adult patients participating in cancer control trials. Oncol Nurs Forum 27:623–630
32.
Zurück zum Zitat Verhoef MJ, Hilsden RJ, O’Beirne M (1999) Complementary therapies and cancer care: an overview. Patient Educ Couns 38:93–100 Verhoef MJ, Hilsden RJ, O’Beirne M (1999) Complementary therapies and cancer care: an overview. Patient Educ Couns 38:93–100
33.
Zurück zum Zitat White JD (2002) Complementary and alternative medicine research: a National Cancer Institute perspective. Semin Oncol 29:546–551 White JD (2002) Complementary and alternative medicine research: a National Cancer Institute perspective. Semin Oncol 29:546–551
Metadaten
Titel
Prevalence of complementary and alternative medicine use in cancer patients during treatment
verfasst von
Jennifer S. Yates
Karen M. Mustian
Gary R. Morrow
Leslie J. Gillies
Devi Padmanaban
James N. Atkins
Brian Issell
Jeffrey J. Kirshner
Lauren K. Colman
Publikationsdatum
01.10.2005
Erschienen in
Supportive Care in Cancer / Ausgabe 10/2005
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-004-0770-7

Weitere Artikel der Ausgabe 10/2005

Supportive Care in Cancer 10/2005 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.